Clinical Trials

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here for more information

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Free Full Text (Free PDF) Free
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pocock, S. J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pocock, S. J
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Clinical Trials, Vol. 3, No. 6, 513-521 (2006)
DOI: 10.1177/1740774506073467
© 2006 The Society for Clinical Trials

Current controversies in data monitoring for clinical trials

Stuart J Pocock

Medical Statistics Unit, London School of Hygiene and Tropical Medicine, London, UK, stuart.pocock{at}lshtm.ac.uk

This article presents some real-life challenges faced by clinical trial Data Monitoring Committees (DMCs), with the aim of clarifying some of the controversial issues that relate to both statistical stopping boundaries and DMC decision-making. Specific attention is given to what constitutes a sensible statistical boundary for stopping a trial early for benefit, bearing in mind that one usually needs proof beyond reasonable doubt of a treatment benefit sufficient to alter future clinical practice. Appropriate choices of stopping boundary for harm and futility are also discussed. The examples serve to illustrate that the practicalities of DMC decision-making require wise judgements based on a totality of evidence, making any statistical boundary just an objective guideline rather than a definitive stopping rule.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Hum ReprodHome page
W. M. Ankum, J. B. Reitsma, and M. Offringa
IVF with preimplantation genetic screening, a promising new treatment with unexpectedly negative health outcomes: the Hippocratic role of Data Monitoring Committees
Hum. Reprod., January 1, 2008; 23(1): 1 - 3.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
S. N. Goodman
Stopping at Nothing? Some Dilemmas of Data Monitoring in Clinical Trials
Ann Intern Med, June 19, 2007; 146(12): 882 - 887.
[Abstract] [Full Text] [PDF]